Amunix: Pouncing on next-gen I/O play, Sanofi acquires Amunix for $1B+ and picks up 'universal mask' tech

Sanofi is crashing the year-end M&A party with a deal of its own. Immuno-oncology is the name of the game as it swallows Mountain View, CA-based Amunix for $1 billion upfront and up to $225 million in biobucks, tagging a suite of T cell engagers and cytokine therapies as well...